Driving Innovation Through Treg Data & Antigen Targeting to Unlock Treg Therapeutic Potential
- Utilize polyclonal Treg data to guide therapeutic direction and inform next-generation cell therapy design
- Highlight PolTREG and Immuthera’s latest Type 1 Diabetes findings to demonstrate clinical progress and therapeutic potential
- Advance disease-specific Treg therapies by leveraging antigen-driven precision for durable immune modulation